SF 2645Session 2025-2026
Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision
Progress
- Introduced
- In committee
- Passed one chamber Not yet
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
Legislative history
-
Senate
Referred to Health and Human Services
-
Senate
Introduction and first reading